BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20130810)

  • 1. Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neck.
    Carlson M; Wuertz B; Lin J; Taylor R; Ondrey F
    Int J Otolaryngol; 2009; 2009():649615. PubMed ID: 20130810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck.
    Willmore-Payne C; Holden JA; Layfield LJ
    Mod Pathol; 2006 May; 19(5):634-40. PubMed ID: 16547470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
    Cohen EE; Lingen MW; Martin LE; Harris PL; Brannigan BW; Haserlat SM; Okimoto RA; Sgroi DC; Dahiya S; Muir B; Clark JR; Rocco JW; Vokes EE; Haber DA; Bell DW
    Clin Cancer Res; 2005 Nov; 11(22):8105-8. PubMed ID: 16299242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
    Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
    Zhang W; Dong X
    J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Frequency and Specific Features of Rare Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma whose Tumors harbor positive EGFR mutations.
    El Yacoubi H; Lemine Sow M; El Ghouti M; Kettani F; Gamra L; Mestari A; Jabri L; Elghissassi I; Errihani H
    Gulf J Oncolog; 2020 May; 1(33):40-44. PubMed ID: 32476648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
    Van Damme N; Deron P; Van Roy N; Demetter P; Bols A; Van Dorpe J; Baert F; Van Laethem JL; Speleman F; Pauwels P; Peeters M
    BMC Cancer; 2010 May; 10():189. PubMed ID: 20459770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
    Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
    Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
    Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
    BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
    Petty WJ; Dragnev KH; Memoli VA; Ma Y; Desai NB; Biddle A; Davis TH; Nugent WC; Memoli N; Hamilton M; Iwata KK; Rigas JR; Dmitrovsky E
    Clin Cancer Res; 2004 Nov; 10(22):7547-54. PubMed ID: 15569985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancer using bi-loop probe specific primer quantitative PCR].
    Wang LS; Zhang Y; Lu XJ; Lu HJ; Zhou L; Wang YS; Deng L; Huang MJ; Peng F; Wang J; Ren L; Hou M; Li L; Xu Y; Ying BW; Lu Y
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):667-70. PubMed ID: 22321544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
    Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
    Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase domain mutations of
    Vatte C; Al Amri AM; Cyrus C; Chathoth S; Acharya S; Hashim TM; Al Ali Z; Alshreadah ST; Alsayyah A; Al-Ali AK
    Onco Targets Ther; 2017; 10():1527-1533. PubMed ID: 28352186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
    Sari M; Aydiner A
    J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.